New drug targeting LF and onchocerciasis begins its first in human trial in Liverpool

A new drug developed by a partnership led by LSTM, which targets neglected tropical diseases, lymphatic filariasis and onchocerciasis, has begun its first human trial. Lymphatic filariasis and onchocerciasis are debilitating diseases that affect more than 150 million people worldwide. Both are caused by parasitic worms, and this specific drug AWZ1066S was designed to targetWolbachia, … Read more